Is VivoSim Labs, Inc. (VIVS) overvalued? · P/E 0.7, rev $131.0K
VivoSim Labs, Inc. (VIVS) is a biotechnology company listed on NASDAQ.
This page asks whether VivoSim Labs, Inc. (VIVS) looks expensive on cached numbers — not a short thesis.
Latest reported VIVS revenue for 2026-03-31 was $131.0K. Net income was -$13.8M. Revenue was down 9.0% from 2025-03-31 to 2026-03-31. VIVS currently screens at market cap $3.5M and trailing P/E 0.7.
VIVS currently screens at market cap $3.5M and trailing P/E 0.7. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next VIVS 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the VIVS stock page for the full model, not this heading.
Not investment advice.